Sunday, December 7, 2025
HomeStocksQ3 results today: Ultratech, Adani Green among 59 companies to announce earnings...

Q3 results today: Ultratech, Adani Green among 59 companies to announce earnings on Thursday

-

[ad_1]

The third quarter earnings season is underway and about 59 companies will announce their results on Thursday. Key results to watch out for include Ultratech Cement, Adani Green, Dr Reddy’s, Mankind Pharma and HPCL.

Apart from the above, companies like ZEE, Cyient, Greaves Cotton, IEX, LKP Securities, Mphasis, Nippon Life AMC, Senores Pharma, Sona BLW Precision and a few others will also declare their quarter results.

Also Read : Catch all Q3 Results 2025 Live Updates Here

Ultratech Cement Q3 expectations

Cement major Ultratech is likely to see a decline in its profitability in the quarter ended December 2024, while the topline may rise marginally.

Revenue from operations during the third quarter could rise just 1% year-on-year (YoY), according to an average estimate of four brokerages. Profit after tax (PAT) may decline 29% YoY.

EBITDA for the quarter is estimated to decline 14% YoY and operating margins may contract 3.1 pp YoY to 16%.Ultratech is seeing pricing pressure from peer group despite having strong branding and market presence. Analysts also expect lower realizations during the quarter mainly on account of weak realization in white cement and clinker sale.Read more: Catch all Stallion India Share Price Live Updates Here.

Dr Reddy’s Q3 expectations

Pharma major Dr Reddy’s is expected to report double-digit growth in both bottomline and topline, led by stable sales in the US and growth in the organic business.

Net profit for the quarter is seen rising 10% year-on-year (YoY), according to an average estimate of four brokerages, while revenues are likely to increase 13% YoY.

Analysts estimate US sales to be stable YoY at $405-427 million, led by limited volume offtake in the differentiated portfolio.

Key factors to watch out for include update on the potential approval in the US over the next 12-18 million, denosumab launch in EU, effect of licenses and partnerships formed in recent years.

(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of Economic Times)

[ad_2]

Source link

LATEST POSTS

Super Villain Origin Story: Conquering Cities with Minions

The story of a super villain’s rise is often shrouded in mystery, ambition, and the desire for ultimate power. From a modest beginning to becoming...

The Future of Ultra-Personalized Video Playlists

The world of streaming is evolving at a pace that few could have predicted a decade ago. What started as simple libraries of shows and...

Professional Franna Crane Operators Serving Northern Sydney

Professional franna crane hire northern sydney play an essential role in ensuring safe, efficient, and reliable lifting operations across a wide range of construction, industrial,...

Experience Endless Gaming Fun Every Day

In today’s digital world, gaming has grown into a daily source of entertainment, creativity, and excitement for millions of people. Whether you enjoy casual mobile...

Most Popular

spot_img